Piscitelli Dominic 4

What Happened
Dominic Piscitelli, CFO of Oric Pharmaceuticals, exercised options to acquire 52,000 shares at $4.36 per share (cost $226,720) on Feb 24, 2026, and those 52,000 shares were sold the same day in an open-market transaction for a weighted-average price of $13.51 per share, generating gross proceeds of approximately $702,686. The Form 4 also reports the related derivative conversion tied to the exercise (shown as a derivative disposition at $0.00), reflecting the options being converted into shares. This sequence (exercise then immediate sale) is effectively a cashless exercise followed by an open-market sale.

Key Details

• Transaction date: February 24, 2026 (reported on Form 4 filed Feb 26, 2026). Filing appears timely.
• Exercise: 52,000 shares at $4.36 → cash paid $226,720.
• Sale: 52,000 shares at weighted-average $13.51 → gross proceeds ~$702,686 (sales reported in range $13.50–$13.53; weighted average per footnote).
• Derivative entry: conversion/ disposition of the option shown at $0.00 (reflects the option being converted/exercised).
• Footnotes: (F1) Sales were made pursuant to a Rule 10b5-1 trading plan adopted June 24, 2025. (F2) Weighted-average price covers sales in the $13.50–$13.53 range; detailed price-by-price breakdown available on request.
• Shares owned after the transaction: not specified in the provided filing.

Context
Because the sale was executed under a pre-established 10b5-1 plan and followed an exercise, this is typically a routine, preplanned transaction rather than an impromptu directional trade. Gross proceeds were ≈$702.7K and the exercise cost was $226.7K, so the approximate net before taxes and fees was ~$476.0K. For retail investors, purchases signal stronger direct insider conviction than routine option exercises followed by sales; the 10b5-1 disclosure is important information about the planned nature of the sale.